Frequently Asked Questions
About Infusing Hizentra

How many infusion sites can be used?

A Hizentra dose may be infused into multiple infusion sites. The number and location of infusion sites depend on the volume of the total dose. Use up to 4 sites simultaneously or up to 12 sites consecutively per infusion. Infusion sites should be at least 2 inches apart. Change the actual site of infusion with each administration. Recommended infusion sites include the thighs, upper arms, stomach, and hips.

How long does it take to infuse?

In the US clinical trial, the median duration of a weekly infusion ranged from 1.6 to 2 hours. Your infusion time may be shorter or longer, depending on the dose and frequency your healthcare provider has prescribed for you. Your experience may vary depending on a number of factors, including number of infusion sites, tubing, and how well you tolerate the treatment.

What infusion equipment is needed?

Supplies include, but are not limited to, infusion pump, needle set(s), and tubing. CSL Behring does not recommend any specific equipment. Your healthcare provider will instruct you on the equipment that's right for you.

At what rate do you infuse Hizentra?

For the first infusion of Hizentra, the recommended maximum flow rate is 15 mL per hour per site. For subsequent infusions, the flow rate may be increased to a maximum of 25 mL per hour per site as tolerated.

What adverse reactions can I expect from infusion with Hizentra?

In the US clinical trial involving 49 patients, most adverse reactions (ARs) reported were non-serious. The most common ARs observed in study subjects were injection-site reactions, headache, vomiting, pain, and fatigue. Please see the full Prescribing Information for a complete list of ARs. Because Hizentra is infused under skin, local reactions are common and expected. The volume per infusion site and overall infusion rate should be adjusted based on patient tolerability. Over 99% of local-site reactions were mild (93.4%) or moderate (6.3%). Symptoms can include swelling, pain, redness, heat or itching at the site of injection.

Can I self-administer Hizentra?

Most patients/caregivers can be trained to infuse. However, self-administration should be done only after you go through training and perform a successful demonstration in front of a healthcare professional. You can always ask your healthcare professional questions about self-administration, especially if you need a refresher or if your infusion regimen has recently changed.

PI Support From a Personal Point of View

Voice2Voice is a unique program that connects Hizentra patients and caregivers with people who know what it's like to live with PI and have direct experience with Hizentra therapy. Because it's good to know you're not alone.

Important Safety Information

Important Safety Information

WARNING: Thrombosis (blood clots) can occur with immune globulin products, including Hizentra. Risk factors can include: advanced age, prolonged immobilization, a history of blood clotting or hyperviscosity (blood thickness), use of estrogens, installed vascular catheters, and cardiovascular risk factors.

If you are at high risk of blood clots, your doctor will prescribe Hizentra at the minimum dose and infusion rate practicable and will monitor for signs of clotting events and hyperviscosity. Always drink sufficient fluids before infusing Hizentra.

See your doctor for a full explanation, and the full prescribing information for complete boxed warning.

Hizentra®, Immune Globulin Subcutaneous (Human), 20% Liquid, is a prescription medicine used to treat:

  • Primary immune deficiency (PI) in patients 2 years and older
  • Chronic inflammatory demyelinating polyneuropathy (CIDP) in adults

Treatment with Hizentra might not be possible if your doctor determines you have hyperprolinemia (too much proline in the blood), or are IgA-deficient with antibodies to IgA and a history of hypersensitivity. Tell your doctor if you have previously had a severe allergic reaction (including anaphylaxis) to the administration of human immune globulin. Tell your doctor right away or go to the emergency room if you have hives, trouble breathing, wheezing, dizziness, or fainting. These could be signs of a bad allergic reaction.

Inform your doctor of any medications you are taking, as well as any medical conditions you may have had, especially if you have a history of diseases related to the heart or blood vessels, or have been immobile for some time. Inform your physician if you are pregnant or nursing, or plan to become pregnant.

Infuse Hizentra under your skin only; do not inject into a blood vessel. Self-administer Hizentra only after having been taught to do so by your doctor or other healthcare professional, and having received dosing instructions for treating your condition.

Immediately report to your physician any of the following symptoms, which could be signs of serious adverse reactions to Hizentra:

  • Reduced urination, sudden weight gain, or swelling in your legs (possible signs of a kidney problem).
  • Pain and/or swelling or discoloration of an arm or leg, unexplained shortness of breath, chest pain or discomfort that worsens on deep breathing, unexplained rapid pulse, or numbness/weakness on one side of the body (possible signs of a blood clot).
  • Bad headache with nausea; vomiting; stiff neck; fever; and sensitivity to light (possible signs of meningitis).
  • Brown or red urine; rapid heart rate; yellowing of the skin or eyes; chest pains or breathing trouble; fever over 100°F (possible symptoms of other conditions that require prompt treatment).

Hizentra is made from human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.

The most common side effects in the clinical trials for Hizentra include redness, swelling, itching, and/or bruising at the infusion site; headache; chest, joint or back pain; diarrhea; tiredness; cough; rash; itching; fever, nausea, and vomiting. These are not the only side effects possible. Tell your doctor about any side effect that bothers you or does not go away.

Before receiving any vaccine, tell immunizing physician if you have had recent therapy with Hizentra, as effectiveness of the vaccine could be compromised.

Please see full prescribing information for Hizentra, including boxed warning and the patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.

CSL Behring
Hizentra is manufactured by CSL Behring AG and distributed by CSL Behring LLC.
Hizentra® and MyHizentra® are registered trademarks of CSL Behring AG.
Biotherapies for Life® is a registered trademark of CSL Behring LLC.
CSL Behring AssuranceSM, IgIQSM, and Premier StartSM are service marks of CSL Behring LLC.
Voice2Voice® is a registered trademark of CSL Behring GmbH.
© 2018 CSL Behring LLC. The product information presented on this site is intended for US residents only. HIZ-0316-MAR18